Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1096443

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1096443

North America Sleep Disorder Treatment Market - Industry Trends and Forecast to 2028

PUBLISHED:
PAGES: 180 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

North America sleep disorder treatment market is projected to register a substantial CAGR of 8.6% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.

Market Segmentation:

North America Sleep Disorder Treatment Market, By Type (Insomnia, Sleep Apnea, Restless Legs Syndrome (RLS), Narcolepsy, and Others), Treatment (Pharmacological Therapy, Mechanical Therapy, Mandibular Advancement Devices, Hypoglossal Nerve Stimulator, Surgery, and Others), Route of Administration (Oral, Parenteral, and Others), Drugs Type (Branded and Generics), Population Type (Children and Adults), End User (Hospitals, Specialty Clinics, Home Healthcare, Ambulatory Surgical Center, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (U.S, Canada and Mexico) Industry Trends and Forecast to 2028.

Some of the major factors contributing to the growth of the North America sleep disorder treatment market are:

  • The growing popularity of mechanical therapy devices to cure sleep disorders across the globe
  • Technological advancements in sleep disorder treatment

Market Players:

The key market players for North America sleep disorder treatment market are listed below:

  • Jazz Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Viatris Inc.
  • Arbor Pharmaceuticals
  • Aurobindo Pharma USA (a subsidiary of Aurobindo Pharma)
  • sanofi-aventis U.S. LLC (a subsidiary of Sanofi)
  • Hikma Pharmaceuticals PLC
  • Amneal Pharmaceuticals LLC
  • Lupin Pharmaceuticals, Inc. (a subsidiary of Lupin)
  • Taj Pharmaceuticals Limited
  • Eli Lilly and Company
  • Mallinckrodt
  • Alembic Pharmaceuticals Limited
  • Apotex Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)
  • Taro Pharmaceutical Industries Ltd.
  • Koninklijke Philips N.V.
  • DeVilbiss Healthcare LLC
  • ResMed
  • SomnoMed
  • Oventus
  • BMC Medical Co.

TABLE OF CONTENTS

1 INTRODUCTION 17

  • 1.1 OBJECTIVES OF THE STUDY 17
  • 1.2 MARKET DEFINITION 17
  • 1.3 OVERVIEW OF NORTH AMERICA SLEEP DISORDER TREATMENT MARKET 17
  • 1.4 CURRENCY AND PRICING 19
  • 1.5 LIMITATIONS 20
  • 1.6 MARKETS COVERED 20

2 MARKET SEGMENTATION 24

  • 2.1 MARKETS COVERED 24
  • 2.2 GEOGRAPHICAL SCOPE 25
  • 2.3 YEARS CONSIDERED FOR THE STUDY 25
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 26
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 29
  • 2.6 MULTIVARIATE MODELLING 30
  • 2.7 TYPE LIFELINE CURVE 30
  • 2.8 DBMR MARKET POSITION GRID 31
  • 2.9 MARKET END USER COVERAGE GRID 33
  • 2.10 SECONDARY SOURCES 34
  • 2.11 ASSUMPTIONS 34

3 EXECUTIVE SUMMARY 35

4 PREMIUM INSIGHT 38

5 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: REGULATIONS 39

6 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: PIPELINE ANALYSIS 41

7 MARKET OVERVIEW 42

  • 7.1 DRIVERS 44
    • 7.1.1 RISING PREVALENCE OF SLEEPING DISORDERS 44
    • 7.1.2 RISE IN THE GERIATRIC POPULATION 45
    • 7.1.3 INCREASE IN MENTAL STRESS DUE TO HECTIC LIFE & UNHEALTHY HABITS 46
    • 7.1.4 LARGE POOL OF UNDIAGNOSED SLEEP APNEA PATIENTS 46
    • 7.1.5 PRESENCE OF POTENTIAL CLINICAL PIPELINE CANDIDATES 47
  • 7.2 RESTRAINTS 48
    • 7.2.1 SIDE EFFECTS ASSOCIATED WITH THESE DRUGS 48
    • 7.2.2 PATENT EXPIRATION OF MAJOR SLEEP DISORDER TREATMENT DRUGS 48
    • 7.2.3 EMERGENCE OF GENERICS 48
  • 7.3 OPPORTUNITIES 50
    • 7.3.1 TECHNOLOGICAL ADVANCEMENTS IN THE SLEEP AIDS IN THE U.S. 50
    • 7.3.2 INCREASING USAGE OF SOCIAL MEDIA AND GROWING ADDICTION OF GADGETS SUCH AS SMARTPHONES AND LAPTOPS 50
    • 7.3.3 GROWING AWARENESS ABOUT TARGET DISEASE 52
  • 7.4 CHALLENGES 53
    • 7.4.1 HIGH COST OF DIAGNOSIS & TREATMENT FOR SLEEPING DISORDER 53
    • 7.4.2 STRINGENT REGULATORY LANDSCAPE 53
    • 7.4.3 POTENTIAL ILL-EFFECTS DUE TO DRUG ABUSE 54

8 IMPACT OF COVID-19 ON NORTH AMERICA SLEEP DISORDER TREATMENT MARKET 55

  • 8.1 PRICE IMPACT 55
  • 8.2 IMPACT ON DEMAND 56
  • 8.3 IMPACT ON SUPPLY CHAIN 56
  • 8.4 STRATEGIC INITIATIVES BY MARKET PLAYERS DURING COVID-19 56
  • 8.5 CONCLUSION 57

9 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE 58

  • 9.1 OVERVIEW 59
  • 9.2 INSOMNIA 62
    • 9.2.1 INSOMNIA 62
    • 9.2.2 CHILD INSOMNIA 62
    • 9.2.3 OTHERS 62
  • 9.3 SLEEP APNEA 63
    • 9.3.1 OBSTRUCTIVE SLEEP APNEA 63
    • 9.3.2 CENTRAL SLEEP APNEA 63
    • 9.3.3 SNORING 63
    • 9.3.4 INFANT SLEEP APNEA 64
    • 9.3.5 OTHERS 64
  • 9.4 RESTLESS LEGS SYNDROME (RLS) 64
  • 9.5 NARCOLEPSY 64
    • 9.5.1 TYPE 1 65
    • 9.5.2 TYPE 2 65

10 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 66

  • 10.1 OVERVIEW 67
  • 10.2 PHARMACOLOGICAL THERAPY 70
    • 10.2.1 CANNABIDIOL 71
    • 10.2.2 ANTI-PARKINSONIAN DRUGS (DOPAMINE AGONISTS) 71
    • 10.2.3 BENZODIAZEPINES 71
    • 10.2.4 NON-BENZODIAZEPINE 71
    • 10.2.5 MELATONIN RECEPTOR STIMULATOR 71
    • 10.2.6 STIMULANTS 71
    • 10.2.7 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) OR SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) 71
    • 10.2.8 TRICYCLIC ANTIDEPRESSANTS 71
    • 10.2.9 SODIUM OXYBATE (XYREM) 71
    • 10.2.10 OTHERS 72
  • 10.3 MECHANICAL THERAPY 72
    • 10.3.1 CPAP (CONTINUOUS POSITIVE AIRWAY PRESSURE) 72
    • 10.3.2 BI-LEVEL PAP 72
    • 10.3.3 AUTO CPAP OR AUTO BI-LEVEL PAP 73
    • 10.3.4 ADAPTIVE SERVO-VENTILATION (ASV) 73
  • 10.4 MANDIBULAR ADVANCEMENT DEVICES 73
  • 10.5 HYPOGLOSSAL NERVE STIMULATOR 73
  • 10.6 SURGERY 74
    • 10.6.1 SOMNOPLASTY 74
    • 10.6.2 TONSILLECTOMY 74
    • 10.6.3 NASAL SURGERY 74
    • 10.6.4 OTHERS 75
  • 10.7 OTHERS 75

11 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 76

  • 11.1 OVERVIEW 77
  • 11.2 ORAL 80
    • 11.2.1 TABLET 80
    • 11.2.2 PILLS 80
    • 11.2.3 OTHERS 80
  • 11.3 PARENTERAL 81
  • 11.4 OTHERS 81

12 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 82

  • 12.1 OVERVIEW 83
  • 12.2 GENERICS 86
  • 12.3 BRANDED 86
    • 12.3.1 XYREM 87
    • 12.3.2 EFFEXOR XR 87
    • 12.3.3 AMBIEN 87
    • 12.3.4 PRISTIQ 87
    • 12.3.5 ZENZEDI 87
    • 12.3.6 VYVANSE 87
    • 12.3.7 OTHERS 88

13 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE 89

  • 13.1 OVERVIEW 90
  • 13.2 ADULT 93
  • 13.3 CHILDREN 93

14 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY END USER 94

  • 14.1 OVERVIEW 95
  • 14.2 HOSPITALS 98
  • 14.3 SPECIALTY CLINICS 98
  • 14.4 HOME HEALTHCARE 98
  • 14.5 AMBULATORY SURGICAL CENTER 99
  • 14.6 OTHERS 99

15 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL 100

  • 15.1 OVERVIEW 101
  • 15.2 DIRECT TENDER 104
  • 15.3 HOSPITAL PHARMACY 104
  • 15.4 RETAIL PHARMACY 104
  • 15.5 ONLINE PHARMACY 105
  • 15.6 OTHERS 105

16 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY REGION 106

  • 16.1 NORTH AMERICA 107
    • 16.1.1 U.S. 115
    • 16.1.2 CANADA 120
    • 16.1.3 MEXICO 125

17 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: COMPANY LANDSCAPE 130

  • 17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 130

18 SWOT ANALYSIS 131

19 COMPANY PROFILE 132

  • 19.1 JAZZ PHARMACEUTICALS, INC. 132
    • 19.1.1 COMPANY SNAPSHOT 132
    • 19.1.2 REVENUE ANALYSIS 132
    • 19.1.3 PRODUCT PORTFOLIO 133
    • 19.1.4 RECENT DEVELOPMENTS 133
  • 19.2 PFIZER INC. 134
    • 19.2.1 COMPANY SNAPSHOT 134
    • 19.2.2 REVENUE ANALYSIS 134
    • 19.2.3 PRODUCT PORTFOLIO 135
    • 19.2.4 RECENT DEVELOPMENT 135
  • 19.3 ELI LILLY AND COMPANY 136
    • 19.3.1 COMPANY SNAPSHOT 136
    • 19.3.2 REVENUE ANALYSIS 136
    • 19.3.3 COMPANY SHARE ANALYSIS 137
    • 19.3.4 PRODUCT PORTFOLIO 137
    • 19.3.5 RECENT DEVELOPMENTS 137
  • 19.4 VIATRIS INC. 138
    • 19.4.1 COMPANY SNAPSHOT 138
    • 19.4.2 REVENUE ANALYSIS 138
    • 19.4.3 COMPANY SHARE ANALYSIS 139
    • 19.4.4 PRODUCT PORTFOLIO 139
    • 19.4.5 RECENT DEVELOPMENTS 139
  • 19.5 RESMED 140
    • 19.5.1 COMPANY SNAPSHOT 140
    • 19.5.2 REVENUE ANALYSIS 140
    • 19.5.3 PRODUCT PORTFOLIO 141
    • 19.5.4 RECENT DEVELOPMENTS 141
  • 19.6 MALLINCKRODT 142
    • 19.6.1 COMPANY SNAPSHOT 142
    • 19.6.2 REVENUE ANALYSIS 142
    • 19.6.3 PRODUCT PORTFOLIO 143
    • 19.6.4 RECENT DEVELOPMENT 143

  • 19.7 KONINKLIJKE PHILIPS N.V. 144
    • 19.7.1 COMPANY SNAPSHOT 144
    • 19.7.2 REVENUE ANALYSIS 144
    • 19.7.3 PRODUCT PORTFOLIO 145
    • 19.7.4 RECENT DEVELOPMENTS 146
  • 19.8 ALEMBIC PHARMACEUTICALS LIMITED 147
    • 19.8.1 COMPANY SNAPSHOT 147
    • 19.8.2 REVENUE ANALYSIS 147
    • 19.8.3 PRODUCT PORTFOLIO 148
    • 19.8.4 RECENT DEVELOPMENT 148
  • 19.9 AMNEAL PHARMACEUTICALS LLC 149
    • 19.9.1 COMPANY SNAPSHOT 149
    • 19.9.2 REVENUE ANALYSIS 149
    • 19.9.3 PRODUCT PORTFOLIO 150
    • 19.9.4 RECENT DEVELOPMENTS 150
  • 19.10 APOTEX INC. 151
    • 19.10.1 COMPANY SNAPSHOT 151
    • 19.10.2 PRODUCT PORTFOLIO 151
    • 19.10.3 RECENT DEVELOPMENT 151
  • 19.11 ARBOR PHARMACEUTICALS 152
    • 19.11.1 COMPANY SNAPSHOT 152
    • 19.11.2 PRODUCT PORTFOLIO 152
    • 19.11.3 RECENT DEVELOPMENTS 152
  • 19.12 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA) 153
    • 19.12.1 COMPANY SNAPSHOT 153
    • 19.12.2 REVENUE ANALYSIS 153
    • 19.12.3 PRODUCT PORTFOLIO 154
    • 19.12.4 RECENT DEVELOPMENTS 154
  • 19.13 BMC MEDICAL CO. 155
    • 19.13.1 COMPANY SNAPSHOT 155
    • 19.13.2 PRODUCT PORTFOLIO 155
    • 19.13.3 RECENT DEVELOPMENT 156
  • 19.14 DEVILBISS HEALTHCARE LLC 157
    • 19.14.1 COMPANY SNAPSHOT 157
    • 19.14.2 PRODUCT PORTFOLIO 157
  • 19.15 DR. REDDY'S LABORATORIES LTD. 159
    • 19.15.1 COMPANY SNAPSHOT 159
    • 19.15.2 REVENUE ANALYSIS 159
    • 19.15.3 PRODUCT PORTFOLIO 160
    • 19.15.4 RECENT DEVELOPMENT 160
  • 19.16 HIKMA PHARMACEUTICALS PLC 161
    • 19.16.1 COMPANY SNAPSHOT 161
    • 19.16.2 REVENUE ANALYSIS 161
    • 19.16.3 PRODUCT PORTFOLIO 162
    • 19.16.4 RECENT DEVELOPMENTS 162
  • 19.17 LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN) 163
    • 19.17.1 COMPANY SNAPSHOT 163
    • 19.17.2 REVENUE ANALYSIS 163
    • 19.17.3 PRODUCT PORTFOLIO 164
    • 19.17.4 RECENT DEVELOPMENTS 164
  • 19.18 OVENTUS 165
    • 19.18.1 COMPANY SNAPSHOT 165
    • 19.18.2 REVENUE ANALYSIS 165
    • 19.18.3 PRODUCT PORTFOLIO 166
    • 19.18.4 RECENT DEVELOPMENTS 166
  • 19.19 SANOFI-AVENTIS U.S. LLC (A SUBSIDIARY OF SANOFI) 167
    • 19.19.1 COMPANY SNAPSHOT 167
    • 19.19.2 REVENUE ANALYSIS 167
    • 19.19.3 PRODUCT PORTFOLIO 168
    • 19.19.4 RECENT DEVELOPMENTS 168
  • 19.20 SOMNOMED 169
    • 19.20.1 COMPANY SNAPSHOT 169
    • 19.20.2 REVENUE ANALYSIS 169
    • 19.20.3 PRODUCT PORTFOLIO 170
    • 19.20.4 RECENT DEVELOPMENTS 170
  • 19.21 TAJ PHARMACEUTICALS LIMITED 171
    • 19.21.1 COMPANY SNAPSHOT 171
    • 19.21.2 PRODUCT PORTFOLIO 171
    • 19.21.3 RECENT DEVELOPMENT 171
  • 19.22 TARO PHARMACEUTICAL INDUSTRIES LTD. 172
    • 19.22.1 COMPANY SNAPSHOT 172
    • 19.22.2 REVENUE ANALYSIS 172
    • 19.22.3 PRODUCT PORTFOLIO 173
    • 19.22.4 RECENT DEVELOPMENT 173
  • 19.23 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.) 174
    • 19.23.1 COMPANY SNAPSHOT 174
    • 19.23.2 REVENUE ANALYSIS 174
    • 19.23.3 PRODUCT PORTFOLIO 175
    • 19.23.4 RECENT DEVELOPMENTS 175

20 QUESTIONNAIRE 176

21 RELATED REPORTS 180

LIST OF TABLES

  • TABLE 1 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: PIPELINE ANALYSIS 41
  • TABLE 2 GENERIC DRUGS FOR SLEEP DISORDER TREATMENT 49
  • TABLE 3 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 61
  • TABLE 4 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 62
  • TABLE 5 NORTH AMERICA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION 63
  • TABLE 6 NORTH AMERICA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION 65
  • TABLE 7 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION) 69
  • TABLE 8 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION 70
  • TABLE 9 NORTH AMERICA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION 72
  • TABLE 10 NORTH AMERICA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION 74
  • TABLE 11 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION) 79
  • TABLE 12 NORTH AMERICA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION) 80
  • TABLE 13 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION) 85
  • TABLE 14 NORTH AMERICA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION) 87
  • TABLE 15 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION) 92
  • TABLE 16 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 97
  • TABLE 17 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 103
  • TABLE 18 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION) 110
  • TABLE 19 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 110
  • TABLE 20 NORTH AMERICA INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 110
  • TABLE 21 NORTH AMERICA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2019-2028 (USD MILLION) 110
  • TABLE 22 NORTH AMERICA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, 2019-2028 (USD MILLION) 111
  • TABLE 23 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION) 111
  • TABLE 24 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION) 111
  • TABLE 25 NORTH AMERICA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION) 112
  • TABLE 26 NORTH AMERICA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2019-2028 (USD MILLION) 112
  • TABLE 27 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 112
  • TABLE 28 NORTH AMERICA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 112
  • TABLE 29 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 113
  • TABLE 30 NORTH AMERICA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 113
  • TABLE 31 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION) 113
  • TABLE 32 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 114
  • TABLE 33 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 114
  • TABLE 34 U.S. SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 115
  • TABLE 35 U.S. INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 115
  • TABLE 36 U.S. SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE, 2019-2028 (USD MILLION) 115
  • TABLE 37 U.S. NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET ,2019-2028 (USD MILLION) 116
  • TABLE 38 U.S. SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION) 116
  • TABLE 39 U.S. PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT , 2019-2028 (USD MILLION) 116
  • TABLE 40 U.S. MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2019-2028 (USD MILLION) 117
  • TABLE 41 U.S. SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION) 117
  • TABLE 42 U.S. PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 117
  • TABLE 43 U.S. ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 118
  • TABLE 44 U.S. PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 118
  • TABLE 45 U.S. BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 118
  • TABLE 46 U.S. SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION) 118
  • TABLE 47 U.S. SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 119
  • TABLE 48 U.S. SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 119
  • TABLE 49 CANADA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 120
  • TABLE 50 CANADA INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 120
  • TABLE 51 CANADA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE, 2019-2028 (USD MILLION) 120
  • TABLE 52 CANADA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, 2019-2028 (USD MILLION) 121
  • TABLE 53 CANADA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION) 121
  • TABLE 54 CANADA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2019-2028 (USD MILLION) 121
  • TABLE 55 CANADA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2019-2028 (USD MILLION) 122
  • TABLE 56 CANADA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION) 122
  • TABLE 57 CANADA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 122
  • TABLE 58 CANADA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 122
  • TABLE 59 CANADA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 123
  • TABLE 60 CANADA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 123
  • TABLE 61 CANADA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION) 123
  • TABLE 62 CANADA SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 124
  • TABLE 63 CANADA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 124
  • TABLE 64 MEXICO SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 125
  • TABLE 65 MEXICO INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 125
  • TABLE 66 MEXICO SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE, 2019-2028 (USD MILLION) 125
  • TABLE 67 MEXICO NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, 2019-2028 (USD MILLION) 126
  • TABLE 68 MEXICO SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION) 126
  • TABLE 69 MEXICO PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION) 126
  • TABLE 70 MEXICO MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION) 127
  • TABLE 71 MEXICO SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION) 127
  • TABLE 72 MEXICO PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 127
  • TABLE 73 MEXICO ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 128
  • TABLE 74 MEXICO PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 128
  • TABLE 75 MEXICO BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 128
  • TABLE 76 MEXICO SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION) 128
  • TABLE 77 MEXICO SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 129
  • TABLE 78 MEXICO SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 129

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: SEGMENTATION 24
  • FIGURE 2 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: DATA TRIANGULATION 26
  • FIGURE 3 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: DROC ANALYSIS 27
  • FIGURE 4 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 28
  • FIGURE 5 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 28
  • FIGURE 6 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 29
  • FIGURE 7 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: DBMR MARKET POSITION GRID 31
  • FIGURE 8 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: MARKET END USER COVERAGE GRID 33
  • FIGURE 9 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: SEGMENTATION 37
  • FIGURE 10 RISING PREVALENCE OF SLEEPING DISORDERS IS EXPECTED TO DRIVE THE NORTH AMERICA SLEEP DISORDER TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028 38
  • FIGURE 11 INSOMNIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA SLEEP DISORDER TREATMENT MARKET IN 2021 & 2028 38
  • FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA SLEEP DISORDER TREATMENT MARKET 43
  • FIGURE 13 PROPORTION OF AMERICAN TEENS (8- TO 12- YEAR-OLD) SPENDING TIME WITH SCREEN MEDIA IN A DAY (IN HOURS) 45
  • FIGURE 14 PROPORTION OF AMERICAN TEENS (8- TO 12- YEAR-OLD) SPENDING TIME WITH SCREEN MEDIA IN A DAY (IN HOURS) 51
  • FIGURE 15 PROPORTION OF AMERICAN TEENS (13- TO 18- YEAR-OLD) SPENDING TIME WITH SCREEN MEDIA IN A DAY (IN HOURS) 52
  • FIGURE 16 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, 2020 59
  • FIGURE 17 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION) 60
  • FIGURE 18 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, CAGR (2020-2028) 60
  • FIGURE 19 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, LIFELINE CURVE 61
  • FIGURE 20 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, 2020 67
  • FIGURE 21 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, 2020-2028 (USD MILLION) 68
  • FIGURE 22 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, CAGR (2020-2028) 68
  • FIGURE 23 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE 69
  • FIGURE 24 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020 77
  • FIGURE 25 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION) 78
  • FIGURE 26 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028) 78
  • FIGURE 27 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 79
  • FIGURE 28 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, 2020 83
  • FIGURE 29 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, 2020-2028 (USD MILLION) 84
  • FIGURE 30 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, CAGR (2020-2028) 84
  • FIGURE 31 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, LIFELINE CURVE 85
  • FIGURE 32 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, 2020 90
  • FIGURE 33 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, 2020-2028 (USD MILLION) 91
  • FIGURE 34 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, CAGR (2020-2028) 91
  • FIGURE 35 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, LIFELINE CURVE 92
  • FIGURE 36 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY END USER, 2020 95
  • FIGURE 37 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION) 96
  • FIGURE 38 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY END USER, CAGR (2020-2028) 96
  • FIGURE 39 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY END USER, LIFELINE CURVE 97
  • FIGURE 40 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020 101
  • FIGURE 41 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION) 102
  • FIGURE 42 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028) 102
  • FIGURE 43 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 103
  • FIGURE 44 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: SNAPSHOT (2020) 107
  • FIGURE 45 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020) 108
  • FIGURE 46 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020 & 2028) 108
  • FIGURE 47 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020 & 2028) 109
  • FIGURE 48 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE (2020-2028) 109
  • FIGURE 49 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: COMPANY SHARE 2020 (%) 130
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!